Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Recognition Of Team Science Faculty Appointments, Promotions and Titles at The Geisel School of Medicine at Dartmouth “Recognition by peers as an investigator whose work has been instrumental in promoting significant advances in her/his field of inquiry, inclusive of basic research, clinical research, pedagogy and health care delivery science. Hallmarks of recognition include both those made as an individual and those made as part of a larger, cooperative team.” Dartmouth Cluster Initiative (e.g., “Big Data”) “Solutions, breakthroughs, and advances often arise from collaborative efforts that transcend the traditional boundaries of academic disciplines. The cluster initiative, through faculty collaboration and targeted hiring, will provide the critical mass and spectrum of expertise necessary to shape and advance the understanding of complex problems, emerging issues, and future societal challenges. The initiative will establish cohorts of scholars focused on new intellectual themes or questions that cut across disciplines, departments, and schools.” Use of Developmental Funds CCSG Developmental Funds Budgeted Uses Pilot Projects New Faculty Shared Resources Technology/Methodology 5y Total $687,853 $315,000 $60,000 $10,000 Programs Cancer Control Cancer Epidemiology Molecular Therapeutics Cancer Mechanisms Cancer Imaging and Radiobiology Immunology and Cancer Immunotherapy Totals Value of peer –reviewed grants for these PIs or as a consequence of pilots Ratio: Peer-reviewed grants/CCSG investment CCSG Supported Number of recruitments supported 1 3 1 1 0 0 Number of CCSG Pilot Awards 7 2 11 1 6 4 6 31 $6,565,802 $16,307,274 21:1 23.7:1 Pilot Projects • NCCC (Prouty): $250,000 • ACS Institutional Grant: $150,000 • Hopeman Cancer Clinical & Population Science: $200,000 • Cancer Nanotechnology: $60,000 • Cancer Comparative Effectiveness • Cancer Program Projects LOIs • LOIs for Foundation Cancer Proposals: V Foundation, Komen Shared Resources add Value to NCCC New Shared Resources and Services: Trace Elements, geospatial Equipment Purchases: 9T MRI, Neogene sequencing platforms Use of Shared Resources Programs CC CE CM MT CIR ICI X X X X X X Trace Elements X X X X X Genomics and Mol. Biol. X X X X X Shared Resource Biostatistics Bioinformatics X X X X X X Immune Monitoring and FC X X X X X X Clinical Pharmacology X X X Irrad.,PreClin. Imag., Micrscpy. X X X X X X X X X X X X X X Pathology Transgenics & Gen. Constructs X X Early Phase Study Program Process 2008 2012 Protocol Specific Research Support 2013 2014 Early Phase Clinical Research Support LoI Process for Early Phase Clinical Research Bench To/from Bedside Formalize Early Phase Trial Clinical Oncology Group LoI Process for Early Phase Clinical Research DH Genetic Research Biobank Molecular Tumor Board NCCC Strategic Plan 2012-2017 41st Year An NCI-Designated Comprehensive Cancer Center MISSION, VISION, and VALUES Research Care & Treatment Innovate to control cancer through research Guide informed decision making by patients and families, and deliver integrated patient care Basic Science & Translation Recognition of the essential value of innovative partnerships between clinical providers and research scientists to improve cancer treatment Prevention Education Improve population health by reducing environmental risk, lifestyle intervention and high value screening Contribute to a sustainable health system by training scientists and doctors in oncology and patient-centered care Population Health & Care Commitment to advance the field: innovation in clinical practice and the technology for high value research People & Resources Accountability for best uses of institutional resources in research, treatment, prevention, and education PERFORMANCE INDICATORS Clinical Trials Patients Accrued to Trials 2012 - 6% 2014 % 2017 ___% Trials Closed w/ Attained Target Accrual 2012 ___% 2014 ___% 2017 ___% Number of D-studies opened annually 2012 - 20 2014 ____ 2017 ____ Completed Quality Improvement Projects Pathway Compliance Tumor Board Case Presentations Shared Resources Provide centrally organized capabilities in 2 new Shared Resources 2014 Registries 2016 Survey Research Increase use or clientele in Shared Resources 2012 _____ 2017 _____ Research Impact Total cancer-related publications 2012 – 426, 2014 ____ 2017 ____ Cancer-related in high-impact journals 2012 ___ 2014 ____ 2017 ____ Total of inter-programmatic collaborative publications 2012 - 47, 2014 ____ 2017 ___ Total of intra-programmatic collaborative publications 2012 – 121, 2014 ____ 2017 ___ Scientists in Tumor Boards 2012 - 3 in 14_ tumor boards 2014 ___ in ___ tumor boards 2017 ___ in ___ tumor boards End of Life Patients with Advance Directives 2012 ___% 2014 ___% 2017 ___ % Documentation of End of Life Discussions 2012 ___% 2014 ___% 2017 ___ % Translation of Prevention Findings to Catchment Area # of citizens involved Diet and Obesity 2012 ___ 2014 ____ 2017 ____ Smoking 2012 ___ 2014 ____ 2017 ____ Sun Safety 2012 ___ 2014 ____ 2017 ____ Screening 2012 ___ 2014 ____ 2017 ____ Improve Patient Experience Willingness to recommend to a friend 2012 ___% 2014 ___% 2017 ___% Patient & Family Services Programs - # of people 2012 ___ 2014 ____ 2017 ____ Translate Scientific Discovery Lead the Nation in Cancer Prevention & Health Promotion 1a. Improve communication mechanisms between investigators and clinicians to promote translational oncology 2a. Expand research resources to support translational and clinical science 3a. Use NCCC discoveries about personal and environmental risk factors to reduce cancer risk for communities 1b.Encourage team science to promote multidisciplinary approaches 2b.Provide Cancer Center resources to remove barriers to conducting Dartmouth investigatorinitiated clinical translational trials 3b..Use population based research in cancer control to inform and optimize primary care practices 1c.Encourage innovative approaches to resolve key questions in basic science, clinical science, and population science to affect public health policy. 2c.Hire Strategically to support translational research Advance Scientific Discovery Hire New Faculty 2012 – 2013 – 10 faculty appointments 2014 - 2015 2016 - 2017 3c. Discover novel approaches to prevent or control cancer development Deliver Patient-Centered Care 0a. Define specific populations and achieve measurable advancement in their health status by providing high value health care 0b. Achieve seamless coordination within NCCC, among external partners, making us the highvalue health system of choice for our region based on a Culture of Caring 0c.. Use quality and safety metrics, health delivery science, and comparative effectiveness to optimize patient outcomes Increase Prouty Funding 2012 $2.6MM 2014 $3.0MM 2017 $3.5MM Peer-Reviewed Funding NIH-approved (incl. NCI) 2012 - $45.8MM 2014 ____ 2017 ____ NCI 2012 - $27.2MM 2014 ____ 2017 ____ Total – all sources 2012 - $61.7MM, 2014 ____ 2017 ____ Pilot Funding for Research Develop Director’s Pilot Funding 2012 - 5, 2014 ____ 2017 ____ Increase Prouty Pilot funding grants 2012 - 7, 2014 ____ 2017 ____ Increase ACS pilot grants 2012 - 5, 2014 ____ 2017 ____ Promote Regional Leadership Steward Resources 5a. Communicate NCCC findings to inform public health policy on a regional and national level 6a. Focus on strengths in areas most likely to impact cancer in humans 5b.Network NCCC providers to partner with region-wide community-based services 6b.Facilitate communication among investigators and promote faculty development to maximize scientific discovery . 5c.Use NCCC’s specialized services and capabilities to provide region wide access to the best cancer health care 6c.Optimize communication to increase awareness of NCCC expertise and services Center Vision Strategic Goals Enhance our translational focus and disseminate trials regionally by hiring 2 physician investigators Discover new imaging strategies and incorporate imaging research into a broader spectrum of research by utilizing the Surgical Innovation Center and Advanced Imaging Center Develop anti-VISTA therapies by expanding clinical immunotherapy group Improve cancer outcomes in our catchment area by expanding our behavioral research. Address emerging issues in cancer care delivery by comparative effectiveness research through increased interaction with TDI Expand ongoing efforts to build global health initiatives by supporting pilot grants in this area. Plans for Future Use Pilot Projects Recruitment (Current) • Cancer Control / • Translational Tobacco Policy • Collaborative • Biostatistics • Interventional • Quantitative • Relevance to Strategic Biomedical Sciences Plan • Cancer Mechanisms • • Early Phase Clinical Development Cancer Immunotherapy